MedTrace Logo

Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus

NCT01129778 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-06-06

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease (GERD) and Barrett's esophagus. Zegerid has been approved by the US Food and Drug Administration (FDA) for the treatment of GERD. The investigators hope to learn the effectiveness of Zegerid for reducing the amount of acid reflux patients are experiencing in the esophagus (swallowing pipe).

Conditions

  • Barrett Esophagus
  • Gastroesophageal Reflux

Interventions

DRUG

Zegerid (proton pump inhibitor)

PROCEDURE

Bravo pH monitoring

Sponsors & Collaborators

Principal Investigators

  • Lauren B Gerson · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-07-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01129778 on ClinicalTrials.gov